SS Innovations International (SSII) Fundamentals 2026 — Revenue Analysis | SniperIQ
SS Innovations International (SSII) is a US-listed Healthcare company in Medical - Devices with a market capitalization of $716M, trading at
SS Innovations International (SSII) has a market capitalization of approximately $716M, trading at
SS Innovations International's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 12.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
SS Innovations International runs a net profit margin of -20.7%, a gross margin of 48.4%, and an operating margin of -12.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
SS Innovations International reported revenue of $42M for fiscal year 2025, with net income of -
SS Innovations International does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
SS Innovations International carries a debt-to-equity ratio of 0.25x and a current ratio of 2.54x, with a market beta of 0.56. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SS Innovations International (SSII) the key facts are: market cap $716M, revenue $42M, 52-week range 3.11-10. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Get SS Innovations International's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.